# Cyclophosphamide for Nasopharyngeal Carcinoma

> **NCT02794077** · PHASE2 · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 56 (actual)

## Conditions studied

- Recurrent Nasopharyngeal Undifferentiated Carcinoma
- Stage IV Nasopharyngeal Undifferentiated Carcinoma

## Interventions

- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02794077
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2015-12
- **Final completion:** 2016-06
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2019-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02794077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02794077, "Cyclophosphamide for Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02794077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*